Elucid is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its groundbreaking product, ElucidVivo, is the first FDA-cleared & CE-marked, histology-validated, non-invasive image analysis software for evaluating CTAs to provide multi-dimensional visualization, structural measurements, & plaque composition to inform risk of an event (heart attack or stroke) and personalized treatment selection.
Our mission is to improve patient outcomes at a reduced cost by applying artificial intelligence to diagnostic imaging. We believe that current cardiovascular diagnostics are often either expensive, burdensome to the patient, or not sufficiently accurate. Medical imaging offers an economically efficient and non-invasive method for capturing patient health information, but additional tools are needed to realize its full diagnostic power. Our software is part of that solution, and we will continue to develop additional applications to support sustainable, enhanced patient care.
Total Funding: $19.4 M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2009
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Elucid
